There are significant challenges in treating mUC
Bladder cancer cases at diagnosis1*
*Based on data from the 2012 to 2018 SEER 17 database.
Bladder cancer represents 4.2% of all new cancer cases in the United States1
- 2022 estimates predicted 81,180 new cases of bladder cancer in the United States1
- Approximately 90% of bladder cancer is urothelial carcinoma2
- Metastatic disease accounts for 5% of all bladder cancers at diagnosis1
Up to 50% of patients develop metastases following surgery for localized disease3
Patients with locally advanced or mUC often present with distinct treatment challenges
- Median age at diagnosis: 73 years1
- Many patients may have comorbidities that impact disease management4,5
- Patients may also have additional complications, such as endocrinopathies, myelosuppression, or peripheral neuropathy6-9
Select comorbidities (≥5%) in patients with Stage IV bladder cancer (2008-2015, N=508)4
Survival rates for mUC are poor
- For patients with bladder cancer, the 5-year relative survival rate is 77.1%1
- For patients with metastatic disease, the 5-year relative survival rate is 7.7%1
5-year relative survival by stage at diagnosis in the United States (2012-2018)1†
†Based on data from the 2012 to 2018 SEER 17 database.
Median OS for patients with mUC is ~13 months for patients who started 1L therapy and ~8 months for patients who started 2L therapy in a real-world US setting10‡
‡Based on retrospective, observational analysis of electronic medical record data from the Flatiron Health longitudinal database in the United States, collected from January 1, 2011 to June 30, 2016, with follow-up through June 30, 2017. Out of 4390 patients diagnosed with urothelial cancer, 1811 qualified for the 1L cohort and 476 qualified for the 2L cohort.
1L=first line; 2L=second line; COPD=chronic obstructive pulmonary disease; OS=Overall Survival; SEER=Surveillance, Epidemiology, and End Results.
References: 1. National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: bladder cancer. Accessed April 27, 2022. https://seer.cancer.gov/statfacts/html/urinb.html 2. Kaseb H, Aeddula NR. Bladder cancer. In: StatPearls [internet]. StatPearls Publishing; 2020. Updated December 1, 2020. Accessed January 24, 2022. https://www.ncbi.nlm.nih.gov/books/NBK536923 3. Svatek RS, Siefker-Radtke A, Dinney CP. Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy. Can Urol Assoc J. 2009;3(6 suppl 4):S228-S231. 4. Fisher MD, Shenolikar R, Miller PJ, Fenton M, Walker MS. Treatment patterns and outcomes in stage IV bladder cancer in a community oncology setting: 2008-2015. Clin Genitourin Cancer. 2018;16(6):e1171-e1179. 5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer V.2.2022. National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed January 19, 2022. To view the most recent and complete version of the guideline, go to NCCN.org. 6. Di Lorenzo G, Buonerba C, Bellelli T, et al. Third-line chemotherapy for metastatic urothelial cancer: a retrospective observational study. Medicine (Baltimore). 2015;94(51):e2297. 7. Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772-781. 8. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13(1):27-46. 9. Siefker-Radtke A, Curti B. Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nat Rev Urol. 2018;15(2):112-124. 10. Simeone JC, Nordstrom BL, Patel K, et al. Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US setting. Cancer Epidemiol. 2019;60:121-127.